Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

L. F. Van Gaal; I. D. Caterson; W. Coutinho; N. Finer; A. P. Maggioni; A. M. Sharma; C. Torp-Pedersen; H. Ge; S. A. Moran; G. M. Shepherd; W. P. T. James; on behalf of the SCOUT Investigators

首页> 外文期刊>Diabetes, Obesity and Metabolism >Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

【24h】

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

机译：糖尿病和非糖尿病高危患者对体重控制和西布曲明的体重和血压反应：西布曲明心血管结局（SCOUT）试验的6周预备期分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To assess treatment responses to sibutramine and weight management in diabetic patients during the lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

机译：目的：在西布曲明心血管结果试验（SCOUT）的引入期间，评估糖尿病患者对西布曲明的治疗反应和体重管理。

著录项

来源
《Diabetes, Obesity and Metabolism》 |2010年第1期|26-34|共9页
作者
L. F. Van Gaal; I. D. Caterson; W. Coutinho; N. Finer; A. P. Maggioni; A. M. Sharma; C. Torp-Pedersen; H. Ge; S. A. Moran; G. M. Shepherd; W. P. T. James; on behalf of the SCOUT Investigators;
展开▼
作者单位

Department of Diabetology Metabolism and Clinical Nutrition Antwerp University Hospital Belgium;

Institute of Obesity Nutrition Exercise University of Sydney Australia;

Endocrinology Obesity Eating Disorders Research Group Catholic University of Rio de Janeiro Brazil;

Department of Medicine University College London London UK;

ANMCO Research Center Florence Italy;

University of Alberta Royal Alexandra Hospital Edmonton Alberta Canada;

Department of Cardiology Gentofte Hospital University of Copenhagen 2900 Hellerup Denmark;

Abbott Laboratories Abbott Park IL USA;

London School of Hygiene and Tropical Medicine London UK;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
antiobesity drugs; CVD risk factors; diabetes; obesity; weight loss;

机译：抗肥胖药;CVD危险因素;糖尿病;肥胖;体重减轻;

相似文献

外文文献
中文文献
专利

1. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. [J] . Van Gaal LF, Caterson ID, Coutinho Diabetes, obesity & metabolism . 2010,第1期

机译：糖尿病和非糖尿病高危患者对体重管理和西布曲明的体重和血压反应：西布曲明心血管预后（SCOUT）试验的6周前期分析。
2. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). [J] . Sharma AM, Caterson ID, Coutinho W, Diabetes, obesity & metabolism . 2009,第3期

机译：与西布曲明和体重管理相关的血压变化-西布曲明心血管预后试验（SCOUT）为期6周的导入期分析。
3. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. [J] . Andersson C, Weeke P, Fosbol EL Metabolism: Clinical and Experimental . 2009,第8期

机译：体重减轻对肥胖，心血管高危患者总胆红素水平的急性影响：Sibutramine心血管结果试验开始期间的一项分析。
4. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period [O] . Peter Weeke, Charlotte Andersson, Emil L Fosbøl, 2010

机译：西布曲明的减肥作用及其对患有和不患有2型糖尿病的心血管高危患者的血脂的影响-来自SCOUT导入期的分析
5. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period [O] . Peter Weeke, Charlotte Andersson, Emil L Fosbøl, 2010

机译：西布曲明的减肥作用及其对患有和不患有2型糖尿病的心血管高危患者的血脂的影响-来自SCOUT导入期的分析

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

摘要

著录项

相似文献

相关主题

期刊订阅